- Home
- REVB vs KTTA Comparison
REVB vs KTTA Comparison
Compare REVB & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- KTTA
- Stock Information
- Founded
- REVB 2020
- KTTA 2020
- Country
- REVB United States
- KTTA United States
- Employees
- REVB N/A
- KTTA N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- KTTA Health Care
- Exchange
- REVB Nasdaq
- KTTA Nasdaq
- Market Cap
- REVB 3.1M
- KTTA 3.5M
- IPO Year
- REVB N/A
- KTTA 2021
- Fundamental
- Price
- REVB $0.80
- KTTA $3.38
- Analyst Decision
- REVB
- KTTA
- Analyst Count
- REVB 0
- KTTA 0
- Target Price
- REVB N/A
- KTTA N/A
- AVG Volume (30 Days)
- REVB 1.3M
- KTTA 29.8K
- Earning Date
- REVB 11-08-2024
- KTTA 11-13-2024
- Dividend Yield
- REVB N/A
- KTTA N/A
- EPS Growth
- REVB N/A
- KTTA N/A
- EPS
- REVB N/A
- KTTA N/A
- Revenue
- REVB N/A
- KTTA N/A
- Revenue This Year
- REVB N/A
- KTTA N/A
- Revenue Next Year
- REVB N/A
- KTTA N/A
- P/E Ratio
- REVB N/A
- KTTA N/A
- Revenue Growth
- REVB N/A
- KTTA N/A
- 52 Week Low
- REVB $0.70
- KTTA $3.19
- 52 Week High
- REVB $25.26
- KTTA $17.40
- Technical
- Relative Strength Index (RSI)
- REVB 44.03
- KTTA 38.62
- Support Level
- REVB $0.80
- KTTA $3.20
- Resistance Level
- REVB $1.05
- KTTA $3.46
- Average True Range (ATR)
- REVB 0.07
- KTTA 0.35
- MACD
- REVB -0.00
- KTTA -0.01
- Stochastic Oscillator
- REVB 9.69
- KTTA 16.38
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.